|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Review |
Department of Neurosurgery [M.N., M.T., H.K., C.-L.Z., Y.S., H.A.], Division of Cell Biology [M.T.], Cancer Institute, Hokkaido University School of Medicine, Kitaku, Sapporo 060-8638, Japan; Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital (CHUV), 1011 Lausanne, Switzerland [N.I., E.G.V.M.]; and Laboratory of Molecular Neuro-Oncology, Department of Neurological Surgery, and Winship Cancer Center, Emory University, Atlanta, GA 30322 [E.G.V.M.]
2 Address correspondence and reprint requests to Mitsuhiro Tada, M.D., Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, N-15 W-7, Kitaku, Sapporo 060-8638, Japan.
Abstract
Loss of function in the p53 tumor suppressor gene due to mutation occurs early in astrocytoma tumorigenesis in about 30–40% of cases. This is believed to confer a growth advantage to the cells, allowing them to clonally expand due to loss of the p53-controlled G1 checkpoint and apoptosis. Genetic instability due to the impaired ability of p53 to mediate DNA damage repair further facilitates the acquisition of new genetic abnormalities, leading to malignant progression of an astrocytoma into anaplastic astrocytoma. This is reflected by a high rate of p53 mutation (60–70%) in anaplastic astrocytomas. The cell cycle control gets further compromised in astrocytoma by alterations in one of the G1/S transition control genes, either loss of the p16/CDKN2 or RB genes or amplification of the cyclin D gene. The final progression process leading to glioblastoma multiforme seems to need additional genetic abnormalities in the long arm of chromosome 10; one of which is deletion and/or functional loss of the PTEN/MMAC1 gene. Glioblastomas also occur as primary (de novo) lesions in patients of older age, without p53 gene loss but with amplification of the epidermal growth factor receptor (EGFR) gene. In contrast to the secondary glioblastomas that evolve from astrocytoma cells with p53 mutations in younger patients, primary glioblastomas seem to be resistant to radiation therapy and thus show a poorer prognosis. The evaluation and design of therapeutic modalities aimed at preventing malignant progression of astrocytomas and glioblastomas should now be based on stratifying patients with astrocytic tumors according to their genetic diagnosis.
References
Adesina, A.M., Nalbantoglu, J., and Cavenee, W.K.
(1994) p53 gene mutation and mdm2 gene amplification are uncommon
in medulloblastoma. Cancer Res.
54,5649
-5651.
Adnane, J., Shao, Z., and Robbins, P.D. (1995) The
retinoblastoma susceptibility gene product represses transcription when
directly bound to the promoter. J. Biol. Chem.
270,8837
-8843.
Agapova, L.S., Ilyinskaya, G.V., Turovets, N.A., Ivanov, A.V., Chumakov, P.M., and Kopnin, B.P. (1996) Chromosome changes caused by alterations of p53 expression. Mutat. Res. 354,129 -138.[CrossRef][ISI][Medline]
Agoff, S. N., Hou, J., Linzer, D. I., and Wu, B.
(1993) Regulation of the human hsp70 promoter by p53.
Science 259,84
-87.
Albarosa, R., Colombo, B.M., Roz, L., Magnani, I., Pollo, B., Cirenei, N., Giani, C., Conti, A.M., DiDonato, S., and Finocchiaro, G. (1996) Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am. J. Hum. Genet. 58,1260 -1267.[ISI][Medline]
Allday, M.J., Inman, G.J., Crawford, D.H., and Farrell, P.J. (1995) DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J. 14,4994 -5005.[ISI][Medline]
Arap, W., Nishikawa, R., Furnari, F.B., Cavenee, W.K., and Huang,
H.J. (1995) Replacement of the p16/CDKN2 gene suppresses human
glioma cell growth. Cancer Res.
55,1351
-1354.
Badiali, M., Iolascon, A., Loda, M., Scheithauer, B.W., Basso, G., Trentini, G.P., and Giangaspero, F. (1993) p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagn. Mol. Pathol. 2,23 -28.[ISI][Medline]
Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993) Mdm2 expression is induced by wild type p53 activity. EMBO J. 12,461 -468.[ISI][Medline]
Barker, F.G., II, Davis, R.L., Chang, S.M., and Prados, M.D. (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77,1161 -1166.[CrossRef][ISI][Medline]
Bello, M.J., Vaquero, J., de Campos, J.M., Kusak, M.E., Sarasa, J.L., Saez-Castresana, J., Pestana, A., and Rey, J.A. (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int. J. Cancer 57,172 -175.[ISI][Medline]
Bian, J., and Sun, Y. (1997) p53CP, a putative p53
competing protein that specifically binds to the consensus p53 DNA binding
sites: A third member of the p53 family? Proc. Natl. Acad. Sci.
USA 94,14753
-14758.
Biernat, W., Kleihues, P., Yonekawa, Y., and Ohgaki, H. (1997a) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56,180 -185.[ISI][Medline]
Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997b) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. (Berl.) 94,303 -309.[CrossRef][Medline]
Bögler, O., Huang, H.J., and Cavenee, W.K. (1995)
Loss of wild-type p53 bestows a growth advantage on primary cortical
astrocytes and facilitates their in vitro transformation. Cancer
Res. 55,2746
-2751.
Boström, J., Cobbers, J.M., Wolter, M., Tabatabai, G., Weber,
R.G., Lichter, P., Collins, V.P., and Reifenberger, G. (1998)
Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of
glioblastomas but not in meningiomas with loss of chromosome arm 10q.
Cancer Res. 58,29
-33.
Brown-Shimer, S., Johnson, K.A., Hill, D.E., and Bruskin, A.M.
(1992) Effect of protein tyrosine phosphatase 1B expression on
transformation by the human neu oncogene. Cancer Res.
52,478
-482.
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B.R., and Kley, N. (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377,646 -649.[CrossRef][Medline]
Buckbinder, L., Velasco-Miguel, S., Chen, Y., Xu, N., Talbott, R.,
Gelbert, L., Gao, J., Seizinger, B.R., Gutkind, J.S., and Kley, N.
(1997) The p53 tumor suppressor targets a novel regulator of G
protein signaling. Proc. Natl. Acad. Sci. USA
94,7868
-7872.
Carrier, F., Smith, M.L., Bae, I., Kilpatrick, K.E., Lansing, T.J.,
Chen, C.Y., Engelstein, M., Friend, S.H., Henner, W.D., and Gilmer, T.M.
(1994) Characterization of human GADD45, a p53-regulated protein.
J. Biol. Chem. 269,32672
-32677.
Chan, F.K., Zhang, J., Cheng, L., Shapiro, D.N., and Winoto, A. (1995) Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol. Cell. Biol. 15,2682 -2688.[Abstract]
Chattopadhyay, P., Rathore, A., Mathur, M., Sarkar, C., Mahapatra, A. K., and Sinha, S. (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene 15,871 -874.[CrossRef][ISI][Medline]
Chen, J., Wu, X., Lin, J., and Levine, A.J. (1996) Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16,2445 -2452.[Abstract]
Cheng, E.H., Kirsch, D.G., Clem, R.J., Ravi, R., Kastan, M.B.,
Bedi, A., Ueno, K., and Hardwick, J.M. (1997) Conversion of Bcl-2
to a Bax-like death effector by caspases. Science
278,1966
-1968.
Chiariello, E., Roz, L., Albarosa, R., Magnani, I., and Finocchiaro, G. (1998) PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 16,541 -545.[CrossRef][ISI][Medline]
Chozick, B. S., Weicker, M. E., Pezzullo, J. C., Jackson, C. L., Finkelstein, S. D., Ambler, M. W., Epstein, M. H., and Finch, P. W. (1994) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73,406 -415.[CrossRef][ISI][Medline]
Chung, R., Whaley, J., Kley, N., Anderson, K., Louis, D., Menon, A., Hettlich, C., Freiman, R., Hedley Whyte, E. T., and Martuza, R. (1991) p53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer 3, 323-331.[ISI][Medline]
Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L., and Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362,849 -852.[CrossRef][Medline]
Costanzi-Strauss, E., Strauss, B.E., Naviaux, R.K., and Haas, M. (1998) Restoration of growth arrest by p16(INK4), p21(WAF1), pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp. Cell Res. 238,51 -62.[CrossRef][ISI][Medline]
Costello, J.F., Plass, C., Arap, W., Chapman, V.M., Held, W.A.,
Berger, M.S., Su Huang, H.J., and Cavenee, W.K. (1997)
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified
using two-dimensional separation of genomic DNA. Cancer
Res. 57,1250
-1254.
Cote, R.J., Esrig, D., Groshen, S., Jones, P.A., and Skinner, D.G. (1997) p53 and treatment of bladder cancer. Nature 385,123 -125.[Medline]
Deb, S.P., Munoz, R.M., Brown, D.R., Subler, M.A., and Deb, S. (1994) Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9,1341 -1349.[ISI][Medline]
Desdouets, C., Ory, C., Matesic, G., Soussi, T., Brechot, C., and Sobczak Thepot, J. (1996) ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. FEBS Lett. 385,34 -38.[CrossRef][ISI][Medline]
Diedrich, U., Lucius, J., Baron, E., Behnke, J., Pabst, B., and Zoll, B. (1995) Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J. Neurol. 242,683 -688.[CrossRef][ISI][Medline]
Dubs-Poterszman, M.C., Tocque, B., and Wasylyk, B. (1995) MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11,2445 -2449.[ISI][Medline]
Ekstrand, A.J., James, C.D., Cavenee, W.K., Seliger, B.,
Pettersson, R.F., and Collins, V.P. (1991) Genes for epidermal
growth factor receptor, transforming growth factor alpha, and epidermal growth
factor and their expression in human gliomas in vivo. Cancer
Res. 51,2164
-2172.
Ekstrand, A.J., Sugawa, N., James, C.D., and Collins, V.P.
(1992) Amplified and rearranged epidermal growth factor receptor
genes in human glioblastomas reveal deletion of sequences encoding portions of
the N- and/or C-terminal tails. Proc. Natl. Acad. Sci.
USA 89,4309
-4313.
Elledge, R.M., and Lee, W.H. (1995) Life and death by p53. Bioessays 17,923 -930.[CrossRef][ISI][Medline]
Fan, S., Smith, M.L., Rivet, D.J., II, Duba, D., Zhan, Q., Kohn,
K.W., Fornace, A.J., Jr., and O'Connor, P.M. (1995) Disruption of
p53 function sensitizes breast cancer MCF-7 cells to cisplatin and
pentoxifylline. Cancer Res.
55,1649
-1654.
Fattman, C.L., An, B., and Dou, Q.P. (1997) Characterization of interior cleavage of retinoblastoma protein in apoptosis. J. Cell. Biochem. 67,399 -408.[CrossRef][ISI][Medline]
Fink, K.L., Rushing, E.J., Schold, S.C. J., Jr., and Nisen, P.D. (1996) Infrequency of p53 gene mutations in ependymomas. J. Neurooncol. 27,111 -115.[Medline]
Flaman, J.-M., Frebourg, T., Moreau, V., Charbonnier, F., Martin,
C., Chappuis, P., Sappino, A.-P., Limacher, I.-M., Bron, L., Benhattar, J.,
Tada, M., Van Meir, E.G., Estreicher, A., and Iggo, R.D. (1995) A
simple p53 functional assay for screening cell lines, blood, and tumors.
Proc. Natl. Acad. Sci. USA
92,3963
-3967.
Forrester, K., Ambs, S., Lupold, S.E., Kapust, R.B., Spillare,
E.A., Weinberg, W.C., Felley Bosco, E., Wang, X.W., Geller, D.A., Tzeng, E.,
Billiar, T.R., and Harris, C.C. (1996) Nitric oxide-induced p53
accumulation and regulation of inducible nitric oxide synthase expression by
wild-type p53. Proc. Natl. Acad. Sci. USA
93,2442
-2447.
Frankel, R.H., Bayona, W., Koslow, M., and Newcomb, E.W.
(1992) p53 mutations in human malignant gliomas: Comparison of
loss of heterozygosity with mutation frequency. Cancer
Res. 52,1427
-1433.
Fu, Y.H.F., Nishinaka, T., Yokoyama, K., and Chiu, R. (1998) A retinoblastoma susceptibility gene product, RB, targeting protease is regulated through the cell cycle. FEBS Lett. 421,89 -93.[CrossRef][ISI][Medline]
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G.F. (1996) Abnormal centrosome amplification in the absence of p53. Science 271,1744 -1747.[Abstract]
Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A., and
Cawthon, R.M. (1992) p53 mutation and loss of heterozygosity on
chromosomes 17 and 10 during human astrocytoma progression. Cancer
Res. 52,674
-679.
Furnari, F.B., Lin, H., Huang, H.J. S., and Cavenee, W.K.
(1997) Growth suppression of glioma cells by PTEN requires a
functional phosphatase catalytic domain. Proc. Natl. Acad. Sci.
USA 94,12479
-12484.
Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M.
(1991) Wild-type p53 can down-modulate the activity of various
promoters. Proc. Natl. Acad. Sci. USA
88,9979
-9983.
Gomez-Manzano, C., Fueyo, J., Kyritsis, A.P., McDonnell, T.J.,
Steck, P.A., Levin, V.A., and Yung, W.K. (1997) Characterization
of p53 and p21 functional interactions in glioma cells en route to apoptosis.
J. Natl. Cancer Inst.
89,1036
-1044.
Guan, K.L., Jenkins, C.W., Li, Y., Nichols, M.A., Wu, X., O'Keefe,
C.L., Matera, A.G., and Xiong, Y. (1994) Growth suppression by
p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with
wild-type pRb function. Genes Dev.
8,2939
-2952.
Hannon, G.J., and Beach, D. (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371,257 -261.[CrossRef][Medline]
Harris, L.C., Remack, J.S., Houghton, P.J. and Brent, T.P.
(1996) Wild-type p53 suppresses transcription of the human
O6-methylguanine-DNA methyl-transferase gene. Cancer
Res. 56,2029
-2032.
Haupt, Y., Barak, Y., and Oren, M. (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15,1596 -1606.[ISI][Medline]
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387,296 -299.[CrossRef][Medline]
Hayashi, Y., Ueki, K., Waha, A., Wiestler, O.D., Louis, D.N., and von Deimling, A. (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol. 7,871 -875.[ISI][Medline]
Hegi, M.E., Zur Hausen, A., Ruedi, D., Malin, G., and Kleihues, P. (1997) Hemizygous or homozygous deletion of the chromosomal region containing the p16(INK4a) gene is associated with amplification of the EGF receptor gene in glioblastomas. Int. J. Cancer 73, 57-63.[CrossRef][ISI][Medline]
Hirai, H., Roussel, M.F., Kato, J.Y., Ashmun, R.A., and Sherr, C.J. (1995) Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15,2672 -2681.[Abstract]
Hollander, M.C., Alamo, I., Jackman, J., Wang, M.G., McBride, O.W.,
and Fornace, A.J., Jr. (1993) Analysis of the mammalian gadd45
gene and its response to DNA damage. J. Biol. Chem.
268,24385
-24393.
Hsieh, J.K., Fredersdorf, S., Kouzarides, T., Martin, K., and Lu,
X. (1997) E2F1-induced apoptosis requires DNA binding but not
transactivation and is inhibited by the retinoblastoma protein through direct
interaction. Genes Dev.
11,1840
-1852.
Hsieh, L.-L., Hsia, C.-F., Wang, L.-Y., Chen, C.-J,. and Ho, Y.-S. (1994) p53 gene mutations in brain tumors in Taiwan. Cancer Lett. 78,25 -32.[CrossRef][ISI][Medline]
Hsu, S.C., Volpert, O.V., Steck, P.A., Mikkelsen, T., Polverini,
P.J., Rao, S., Chou, P., and Bouck, N.P. (1996) Inhibition of
angiogenesis in human glioblastomas by chromosome 10 induction of
thrombospondin-1. Cancer Res.
56,5684
-5691.
Hunter, S.B., Bandea, C., Swan, D., Abbott, K., and Varma, V.A. (1993) Mutations in the p53 gene in human astrocytomas: Detection by single-strand conformation polymorphism analysis and direct DNA sequencing. Mod. Pathol. 6,442 -445.[ISI][Medline]
Hurtt, M.R., Moossy, J., Donovan-Peluso, M., and Locker, J. (1992) Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J. Neuropathol. Exp. Neurol. 51,84 -90.[ISI][Medline]
Ichimura, K., Schmidt, E.E., Goike, H.M., and Collins, V.P. (1996) Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13,1065 -1072.[ISI][Medline]
Ishii, N., Sawamura, Y., Tada, M., Daub, D.M., Janzer, R.C., Meagher-Villemure, M., de Tribolet, N., and Van Meir, E.G. (1998) Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int. J. Cancer 76,797 -800.[CrossRef][ISI][Medline]
Izumoto, S., Arita, N., Ohnishi, T., Hiraga, S., Taki, T., and Hayakawa, T. (1995) Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett. 97,241 -247.[CrossRef][ISI][Medline]
Jen, J., Harper, J.W., Bigner, S.H., Bigner, D.D., Papadopoulos,
N., Markowitz, S., Willson, J.K., Kinzler, K.W., and Vogelstein, B.
(1994) Deletion of p16 and p15 genes in brain tumors.
Cancer Res. 54,6353
-6358.
Jost, C.A., Marin, M.C., and Kaelin, W.G., Jr. (1997) p73 is a human p53-related protein that can induce apoptosis. Nature 389,191 -194.[CrossRef][Medline]
Jung, J.M., Bruner, J.M., Ruan, S., Langford, L.A., Kyritsis, A.P., Kobayashi, T., Levin, V.A., and Zhang, W. (1995) Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 11,2021 -2028.[ISI][Medline]
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C., Valent, A., Minty, A., Chalon, P., Lelias, J.M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90,809 -819.[CrossRef][ISI][Medline]
Kamb, A., Gruis, N.A., Weaver Feldhaus, J., Liu, Q., Harshman, K.,
Tavtigian, S.V., Stockert, E., Day, R.S., III, Johnson, B.E., and Skolnick,
M.H. (1994) A cell cycle regulator potentially involved in
genesis of many tumor types. Science
264,436
-440.
Karlbom, A.., James, C.D., Boethius, J., Cavenee, W.K., Collins, V.P., Nordenskjold, M., and Larsson, C. (1993) Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum. Genet. 92,169 -174.[ISI][Medline]
Kashiwazaki, H., Tonoki, H., Tada, M., Chiba, I., Shindoh, M., Totsuka, Y., Iggo, R., and Moriuchi, T. (1997) High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 15,2667 -2674.[CrossRef][ISI][Medline]
Kieser, A., Weich, H.A., Brandner, G., Marme, D., and Kolch, W. (1994) Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9,963 -969.[ISI][Medline]
Kleihues, P., Burger, P.C., and Scheithauer, B.W. (1993) Histological typing of tumours of the central nervous system. Berlin: Springer Verlag.
Kluck, R.M., Martin, S.J., Hoffman, B.M., Zhou, J.S., Green, D.R., and Newmeyer, D.D. (1997) Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system EMBO J. 16,4639 -4649.[CrossRef][ISI][Medline]
Kondo, S., Barna, B.P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J.W., Werbel, B., and Barnett, G.H. (1996) WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 13,1279 -1285.[ISI][Medline]
Kraus, J.A., Bolln, C., Wolf, H.K., Neumann, J., Kindermann, D., Fimmers, R., Forster, F., Baumann, A., and Schlegel, U. (1994) TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10,143 -149.[ISI][Medline]
Kraus, J.A., Koopmann, J., Kaskel, P., Maintz, D., Brandner, S., Schramm, J., Louis, D.N., Wiestler, O.D., and von Deimling, A. (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligoden-droglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 54,91 -95.[ISI][Medline]
Kroemer, G. (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 3, 614-620.[CrossRef][ISI][Medline]
Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature 387,299 -303.[CrossRef][Medline]
Kyritsis, A.P., Bondy, M.L., Xiao, M., Berman, E.L., Cunningham,
J.E., Lee, P.S., Levin, V.A., and Saya, H. (1994) Germline p53
gene mutations in subsets of glioma patients. J. Natl. Cancer.
Inst. 86,344
-349.
Kyritsis, A.P., Zhang, B., Zhang, W., Xiao, M., Takeshima, H., Bondy, M.L., Cunningham, J.E., Levin, V.A., and Bruner, J. (1996) Mutations of the p16 gene in gliomas. Oncogene 12, 63-67.[ISI][Medline]
Lang, F.F., Miller, D.C., Koslow, M., and Newcomb, E.W. (1994a) Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 81,427 -436.[ISI][Medline]
Lang, F.F., Miller, D.C., Pisharody, S., Koslow, M., and Newcomb, E.W. (1994b) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9, 949-954.[ISI][Medline]
Leenstra, S., Bijlsma, E.K., Troost, D., Oosting, J., Westerveld, A., Bosch, D.A., and Hulsebos, T.J. (1994) Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br. J. Cancer 70,684 -689.[ISI][Medline]
Li, H., Bergeron, L., Cryns, V., Pasternack, M.S., Zhu, H., Shi,
L., Greenberg, A., and Yuan, J. (1997) Activation of caspase-2 in
apoptosis. J. Biol. Chem.
272,21010
-21017.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I.,
Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S.H., Giovanella,
B.C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M.H., and Parsons, R.
(1997) PTEN, a putative protein tyrosine phosphatase gene mutated
in human brain, breast, and prostate cancer. Science
275,1943
-1947.
Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., Eng, C., and Parsons, R. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16,64 -67.[CrossRef][ISI][Medline]
Litofsky, N.S., Hinton, D., and Raffel, C. (1994) The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 34,967 -972.[ISI][Medline]
Liu, P.K., Kraus, E., Wu, T.A., Strong, L.C., and Tainsky, M.A. (1996) Analysis of genomic instability in Li-Fraumenifibroblasts with germline p53 mutations. Oncogene 12,2267 -2278.[ISI][Medline]
Liu, W., James, C.D., Frederick, L., Alderete, B.E., and Jenkins,
R.B. (1997) PTEN/MMAC1 mutations and EGFR amplification in
glioblastomas. Cancer Res.
57,5254
-5257.
Louis, D.N., Rubio, M.-P., Correa, K.M., Gusella, J.F., and von Deimling, A. (1993a) Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J. Neuropathol. Exp. Neurol. 52,507 -515.[ISI][Medline]
Louis, D.N., von Deimling, A., Chung, R.Y., Rubio, M.P., Whaley, J.M., Eibl, R.H., Ohgaki, H., Wiestler, O.D., Thor, A.D., and Seizinger, B.R. (1993b) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol. 52, 31-38.[ISI][Medline]
Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74,957 -967.[CrossRef][ISI][Medline]
Ludes Meyers, J.H., Subler, M.A., Shivakumar, C.V., Munoz, R.M., Jiang, P., Bigger, J.E., Brown, D.R., Deb, S.P., and Deb, S. (1996) Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16,6009 -6019.[Abstract]
Mack, D.H., Vartikar, J., Pipas, J.M., and Laimins, L.A. (1993) Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363,281 -283.[CrossRef][Medline]
Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D.J., Smith,
D.I., and Liu, W. (1998) Activation of p73 silent allele in lung
cancer. Cancer Res. 58,2347
-2349.
Maintz, D., Fiedler, K., Koopmann, J., Rollbrocker, B., Nechev, S., Lenartz, D., Stangl, A.P., Louis, D.N., Schramm, J., Wiestler, O.D., and von Deimling, A. (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56,1098 -1104.[ISI][Medline]
Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F., Jr., Nelson,
C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., and Tainsky, M.A. et
al. (1990) Germ line p53 mutations in a familial syndrome of
breast cancer, sarcomas, and other neoplasms. Science
250,1233
-1238.
Margulies, L., and Sehgal, P.B. (1993) Modulation of
the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta
(NF-IL6) activity by p53 species. J. Biol. Chem.
268,15096
-15100.
Marsh, D.J., Dahia, P.L., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R.J. and Eng, C. (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 16,333 -334.[CrossRef][ISI][Medline]
Martin, K., Trouche, D., Hagemeier, C., Sfrensen, T.S., La Thangue, N.B., and Kouzarides, T. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375,691 -694.[CrossRef][Medline]
Mashiyama, S., Murakami, Y., Yoshimoto, T., Sekiya, T., and Hayashi, K. (1991) Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6,1313 -1318.[ISI][Medline]
Matsumoto, R., Tada, M., Nozaki, M., Zhang, C.-L., Sawamura, Y., and Abe, H. (1998) Short alternative splice transcripts of Mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58,608 -613.
Mercer, W.E., Shields, M.T., Amin, M., Sauve, G.J., Appella, E.,
Romano, J.W., and Ullrich, S.J. (1990) Negative growth regulation
in a glioblastoma tumor cell line that conditionally expresses human wild-type
p53. Proc. Natl. Acad. Sci. USA
87,6166
-6170.
Metzger, A.K., Sheffield, V.C., Duyk, G., Daneshvar, L., Edwards,
M.S., and Cogen, P.H. (1991) Identification of a germ-line
mutation in the p53 gene in a patient with an intracranial ependymona.
Proc. Natl. Acad. Sci. USA
88,7825
-7829.
Meyer-Puttlitz, B., Hayashi, Y., Waha, A., Rollbrocker, B., Bostrom, J., Wiestler, O.D., Louis, D.N., Reifenberger, G., and von Deimling, A. (1997) Molecular genetic analysis of giant cell glioblastomas. Am. J. Pathol. 151,853 -857.[Abstract]
Miyakoshi, J., Kitagawa, K., Yamagishi, N., Ohtsu, S., Day, R.S., III, and Takebe, H. (1997) Increased radiosensitivity of p16 gene-deleted human glioma cells after transfection with wild-type p16 gene. Jpn. J. Cancer Res. 88,34 -38.[ISI][Medline]
Miyashita, T., and Reed, J.C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80,293 -299.[CrossRef][ISI][Medline]
Miyashita, T., Harigai, M., Hanada, M., and Reed, J.C.
(1994) Identification of a p53-dependent negative response
element in the bcl-2 gene. Cancer Res.
54,3131
-3135.
Mollenhauer, J., Wiemann, S., Scheurlen, W., Korn, B., Hayashi, Y., Wilgenbus, K.K., von Deimling, A., and Poustka, A. (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat. Genet. 17, 32-39.[CrossRef][ISI][Medline]
Momand, J., Zambetti, G.P., Olson, D.C., George, D.L., and Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69,1237 -1245.[CrossRef][ISI][Medline]
Morris, G.F., Bischoff, J.R., and Mathews, M.B. (1996)
Transcriptional activation of the human proliferating-cell nuclear antigen
promoter by p53. Proc. Natl. Acad. Sci. USA
93,895
-899.
Moulton, T., Samara, G., Chung, W.., Yuan, L., Desai, R., Sisti, M., Bruce, J., and Tycko, B. (1995) MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am. J. Pathol. 146,613 -619.[Abstract]
Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V.P.
(1995) Wild-type p53 and v-Src exert opposing influences on human
vascular endothelial growth factor gene expression. Cancer
Res. 55,6161
-6165.
Muller, W., Afra, D., and Schroder, R. (1977) Supratentorial recurrence of gliomas. Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir. 37, 75-91.
Myers, M.P., Stolarov, J.P., Eng, C., Li, J., Wang, S.I., Wigler,
M.H., Parsons, R., and Tonks, N.K. (1997) P-TEN, the tumor
suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
Proc. Natl. Acad. Sci. USA
94,9052
-9057.
Nakamura, H., Yoshida, M., Tsuiki, H., Ito, K., Ueno, M., Nakao, M., Oka, K., Tada, M., Kochi, M., Kuratsu, J.-I., Ushio, Y., and Saya, H. (1998) Identi-fication of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 16,1009 -1019.[CrossRef][ISI][Medline]
Newcomb, E.W., Madonia, W.J., Pisharody, S., Lang, F.F., Koslow, M., and Miller, D.C. (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol. 3,229 -235.[ISI][Medline]
Nishikawa, R., Ji, X.D., Harmon, R.C., Lazar, C.S., Gill, G.N.,
Cavenee, W.K., and Huang, H.J. (1994) A mutant epidermal growth
factor receptor common in human glioma confers enhanced tumorigenicity.
Proc. Natl. Acad. Sci. USA
91,7727
-7731.
Nomoto, S., Haruki, N., Kondo, M., Konishi, H., Takahashi, T.,
Takahashi, T., and Takahashi, T. (1998) Search for mutations and
examination of allelic expression imbalance of the p73 gene at 1p36.33 in
human lung cancers. Cancer Res.
58,1380
-1383.
Nozaki, M., Tada, M., Matsumoto, R., Sawamura, Y., Abe, H., and Iggo, R.D. (1998) Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: Reappraisal by yeast functional assay. Acta Neuropathol. 95,291 -296.
Ohgaki, H., Eibl, R.H., Wiestler, O.D., Yasargil, M.G., Newcomb,
E.W., and Kleihues, P. (1991) p53 mutations in nonastrocytic
human brain tumors. Cancer Res.
51,6202
-6205.
Ohgaki, H., Eibl, R.H., Schwab, M., Reichel, M.B., Mariani, L., Gehring, M., Petersen, I., Holl, T., Wiestler, O.D., and Kleihues, P. (1993) Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol. Carcinog. 8, 74-80.[ISI][Medline]
Okamoto, K., and Beach, D. (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13,4816 -4822.[ISI][Medline]
Olschwang, S., Serova-Sinilnikova, O.M., Lenoir, G.M., and Thomas, G. (1998) PTEN germ-line mutations in juvenile polyposis coli. Nat. Genet. 18,12 -14.[CrossRef][ISI][Medline]
Ono, Y., Tamiya, T., Ichikawa, T., Kunishio, K., Matsumoto, K., Furuta, T., Ohmoto, T., Ueki, K., and Louis, D.N. (1996) Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J. Neuropathol. Exp. Neurol. 55,1026 -1031.[ISI][Medline]
Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4, 839-843.[CrossRef][ISI][Medline]
Patt, S., Gries, H., Giraldo, M., Cervos Navarro, J., Martin, H., Janisch, W., and Brockmoller, J. (1996) p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum. Pathol. 27,586 -589.[CrossRef][ISI][Medline]
Penar, P.L., Khoshyomn, S., Bhushan, A., and Tritton, T.R. (1997) Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 40,141 -151.[CrossRef][ISI][Medline]
Polyak, K., Waldman, T., He, T.C., Kinzler, K.W., and Vogelstein,
B. (1996) Genetic determinants of p53-induced apoptosis and
growth arrest. Genes Dev.
10,1945
-1952.
Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M., and Aloni, Y. (1993) Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8,1183 -1193.[ISI][Medline]
Rainov, N.G., Dobberstein, K.-U., Fittkau, M., Bahn, H., Holzhausen, H.-J., Gantchev, L., and Burkert, W. (1995) Absence of p53 autoantibodies in sera from glioma patients. Clin. Cancer Res. 1,775 -781.[Abstract]
Rasheed, B.K., McLendon, R.E., Herndon, J.E., Friedman, H.S.,
Friedman, A.H., Bigner, D.D., and Bigner, S.H. (1994) Alterations
of the TP53 gene in human gliomas. Cancer Res.
54,1324
-1330.
Rasheed, B.K., McLendon, R.E., Friedman, H.S., Friedman, A.H., Fuchs, H.E., Bigner, D.D., and Bigner, S.H. (1995) Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10,2243 -2246.[ISI][Medline]
Rasheed, B.K., Stenzel, T.T., McLendon, R.E., Parsons, R.,
Friedman, A.H., Friedman, H.S., Bigner, D.D., and Bigner, S.H.
(1997) PTEN gene mutations are seen in high-grade but not in
low-grade gliomas. Cancer Res.
57,4187
-4190.
Reed, J.C. (1997) Double identity for proteins of the Bcl-2 family. Nature 387,773 -776.[CrossRef][Medline]
Reifenberger, G., Reifenberger, J., Ichimura, K., Meltzer, P.S.,
and Collins, V.P. (1994) Amplification of multiple genes from
chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of
the amplicons shows preferential involvement of CDK4, SAS, and MDM2.
Cancer Res. 54,4299
-4303.
Reifenberger, J., Reifenberger, G., Liu, L., James, C.D., Wechsler, W., and Collins, V.P. (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145,1175 -1190.[Abstract]
Reifenberger, J., Ring, G.U., Gies, U., Cobbers, L., Oberstrass, J., An, H.X., Niederacher, D., Wechsler, W., and Reifenberger, G. (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol. 55,822 -831.[ISI][Medline]
Sakuma, S., Saya, H., Tada, M., Nakao, M., Fujiwara, T., Roth, J.A., Sawamura, Y., Shinohe, Y., and Abe, H. (1996) Receptor protein tyrosine kinase DDR is up-regulated by p53 protein. FEBS Lett. 398,165 -169.[CrossRef][ISI][Medline]
Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., and Strauss, M. (1997) Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med. 3,313 -319.[CrossRef][ISI][Medline]
Santhanam, U., Ray, A., and Sehgal, P.B. (1991)
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma
susceptibility gene product. Proc. Natl. Acad. Sci.
USA 88,7605
-7609.
Sarkar, F.H., Kupsky, W.J., Li, Y.-W., and Sreepathi, P. (1994) Analysis of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand conformation polymorphism and DNA sequencing. Diag. Mol. Pathol. 3, 2-8.[ISI][Medline]
Saxena, A., Clark, W.C., Robertson, J.T., Ikejiri, B., Oldfield,
E.H., and Ali, I.U. (1992) Evidence for the involvement of a
potential second tumor suppressor gene on chromosome 17 distinct from p53 in
malignant astrocytomas. Cancer Res.
52,6716
-6721.
Saylors, R.L., III, Sidransky, D., Friedman, H.S., Bigner, S.H.,
Bigner, D.D., Vogelstein, B., and Brodeur, G.M. (1991) Infrequent
p53 gene mutations in medulloblastomas. Cancer Res.
51,4721
-4723.
Scherer, S.J., Welter, C., Zang, K.D., and Dooley, S. (1996) Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem. Biophys. Res. Commun. 221,722 -728.[CrossRef][ISI][Medline]
Schiffer, D., Cavalla, P., Di Sapio, A., Giordana, M.T., and Mauro, A. (1995) Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood. Childs Nerv. Syst. 11,517 -522.[CrossRef][ISI][Medline]
Schlegel, J., Scherthan, H., Arens, N., Stumm, G., and Kiessling, M. (1996) Detection of complex genetic alterations in human glioblastoma multiforme using comparative genomic hybridization. J. Neuropathol. Exp. Neurol. 55,81 -87.[ISI][Medline]
Schmidt, E.E., Ichimura, K., Reifenberger, G., and Collins, V.P.
(1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification
occurs in the majority of glioblastomas. Cancer Res.
54,6321
-6324.
Schmidt, E.E., Ichimura, K., Messerle, K.R., Goike, H.M., and Collins, V.P. (1997) Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br. J. Cancer 75, 2-8.[ISI][Medline]
Serrano, M., Hannon, G.J., and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366,704 -707.[CrossRef][Medline]
Shin, T.H., Paterson, A.J., and Kudlow, J.E. (1995) p53 stimulates transcription from the human transforming growth factor a promoter: A potential growth-stimulatory role for p53. Mol. Cell. Biol. 15,4694 -4701.[Abstract]
Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M.L., Cavenee, W., and Vogelstein, B. (1992) Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355,846 -847.[CrossRef][Medline]
Sonoda, Y., Yoshimoto, T., and Sekiya, T. (1995) Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 11,2145 -2149.[ISI][Medline]
Sorby, M., and Ostman, A. (1996) Protein-tyrosine
phosphatase-mediated decrease of epidermal growth factor and platelet-derived
growth factor receptor tyrosine phosphorylation in high cell density cultures.
J. Biol. Chem. 271,10963
-10966.
Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H., and Tavtigian, S.V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15,356 -362.[CrossRef][ISI][Medline]
Strasser, A., Harris, A.W., Jacks, T., and Cory, S. (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79,329 -339.[CrossRef][ISI][Medline]
Sunahara, M., Ichimiya, S., Nimura, Y., Takada, N., Sakiyama, S., Sato, Y., Todo, S., Adachi, W., Amano, J., and Nakagawara, A. (1998) Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int. J. Oncol. 13,319 -323.[ISI][Medline]
Sure, U., Ruedi, D., Tachibana, O., Yonekawa, Y., Ohgaki, H., Kleihues, P., and Hegi, M.E. (1997) Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J. Neuropathol. Exp. Neurol. 56,782 -789.[ISI][Medline]
Tada, M., Iggo, R.D., Ishii, N., Shinohe, Y., Sakuma, S., Estreicher, A., Sawamura, Y., and Abe, H. (1996) Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int. J. Cancer 67,447 -450.[CrossRef][ISI][Medline]
Tada, M., Iggo, R.D., Waridel, F., Nozaki, M., Matsumoto, R., Sawamura, Y., Shinohe, Y., Ikeda, J., and Abe, H. (1997) Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol. Carcinog. 18,171 -176.[CrossRef][ISI][Medline]
Tada, M., Matsumoto, R., Iggo, R.D., Onimaru, R., Shirato, H.,
Sawamura, Y., and Shinohe, Y. (1998) Selective sensitivity to
radiation of cerebral glioblastomas harboring p53 mutation. Cancer
Res. 58,1793
-1797.
Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato,
M., Wakui, S., Yatani, R., Aizawa, S., and Nakagawara, A. (1998)
Mutation, allelo-typing, and transcription analyses of the p73 gene in
prostatic carcinoma. Cancer Res.
58,2076
-2077.
Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R., and
Yamada, K.M. (1998) Inhibition of cell migration, spreading, and
focal adhesions by tumor suppressor PTEN. Science
280,1614
-1617.
Tang, P., Steck, P.A., and Yung, W.K. (1997) The autocrine loop of TGF-alpha/EGFR and brain tumors. J. Neurooncol. 35,303 -314.[CrossRef][Medline]
Tenan, M., Colombo, B.M., Pollo, B., Cajola, L., Broggi, G., and Finocchiaro, G. (1994) p53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. Cancer Genet. Cytogenet. 74,139 -143.[CrossRef][ISI][Medline]
Tenan, M., Benedetti, S., and Finocchiaro, G. (1995) Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Biochem. Biophys. Res. Commun. 217,195 -202.[CrossRef][ISI][Medline]
Teng, D.H.F., Hu, R., Lin, H., Davis, T., Iliev, D., Frye, C.,
Swedlund, B., Hansen, K.L., Vinson, V.L., Gumpper, K.L., Ellis, L., Elnaggar,
A., Frazier, M., Jasser, S., Langford, L.A., Lee, J., Mills, G.B., Pershouse,
M.A., Pollack, R.E., Tornos, C., Troncoso, P., Yung, W.K., Fujii, G., Berson,
A., and Bookstein, R. (1997) MMAC1/PTEN mutations in primary
tumor specimens and tumor cell lines. Cancer Res.
57,5221
-5225.
Tohma, Y., Gratas, C., Biernat, W., Peraud, A., Fukuda, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57,684 -689.[ISI][Medline]
Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., and Sidransky, D. (1998) A new human p53 homologue. Nat. Med. 4,747 -745.[CrossRef][ISI][Medline]
Tsumanuma, I., Sato, M., Okazaki, H., Tanaka, R., Washiyama, K., Kawasaki, T., and Kumanishi, T. (1995) The analysis of p53 tumor suppressor gene in pineal parenchymal tumors. Noshuyo Byori 12,39 -43.[Medline]
Tsuzuki, T., Tsunoda, S., Sakaki, T., Konishi, N., Hiasa, Y., and Nakamura, M. (1996) Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 78,287 -293.[CrossRef][ISI][Medline]
Ueba, T., Nosaka, T., Takahashi, J.A., Shibata, F., Florkiewicz,
R.Z., Vogelstein, B., Oda, Y., Kikuchi, H., and Hatanaka, M.
(1994) Transcriptional regulation of basicfibroblast growth
factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells.
Proc. Natl. Acad. Sci. USA
91,9009
-9013.
Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimling, A., and
Louis, D.N. (1996) CDKN2/p16 or RB alterations occur in the
majority of glioblastomas and are inversely correlated. Cancer
Res. 56,150
-153.
Uhrbom, L., Nister, M., and Westermark, B. (1997) Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15,505 -514.[CrossRef][ISI][Medline]
Van Meir, E.G., Roemer, K., Diserens, A.., Kikuchi, T., Rempel,
S.A., Haas, M., Huang, H.-J., Friedmann, T., de Tribolet, N., and Cavenee,
W.K. (1995) Single cell monitoring of growth arrest and
morphological changes induced by transfer of wild-type p53 alleles to
glioblastoma cells. Proc. Natl. Acad. Sci. USA
92,1008
-1012.
van Meyel, D.J., Ramsay, D.A., Casson, A.G., Keeney, M., Chambers,
A.F., and Cairncross, J.G. (1994) p53 mutation, expression, and
DNA ploidy in evolving gliomas: Evidence for two pathways of progression.
J. Natl. Cancer Inst.
86,1011
-1017.
von Deimling, A., Eibl, R.H., Ohgaki, H., Louis, D.N., von Ammon,
K., Petersen, I., Kleihues, P., Chung, R.Y., Wiestler, O.D., and Seizinger,
B.R. (1992a) p53 mutations are associated with 17p allelic loss
in grade II and grade III astrocytoma. Cancer Res.
52,2987
-2990.
von Deimling, A., Louis, D.N., von Ammon, K., Petersen, I., Hoell, T., Chung, R.Y., Martuza, R.L., Schoenfeld, D.A., Yasargil, M.G., and Wiestler, O.D. (1992b) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg. 77,295 -301.[ISI][Medline]
von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O.D., Seizinger, B.R., and Louis, D.N. (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3,19 -26.[ISI][Medline]
Wagenknecht, B., Trepel, M., von Deimling, A., Grimmel, C., Rollbrocker, B., Hayashi, Y., Lang, F., Dichgans, J., Gulbins, E., and Weller, M. (1997) p53 accumulation promotes dephosphorylation and proteolytic cleavage of retinoblastoma protein in human malignant glioma cells. Cell. Physiol. Biochem. 7, 304-311.[CrossRef]
Wahl, A.F., Donaldson, K.L., Fairchild, C., Lee, F.Y., Foster, S.A., Demers, G.W., and Galloway, D.A. (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2,72 -79.[CrossRef][ISI][Medline]
Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. (1997) Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 3,1034 -1036.[CrossRef][ISI][Medline]
Wang, S.I., Puc, J., Li, J., Bruce, J.N., Cairns, P., Sidransky,
D., and Parsons, R. (1997) Somatic mutations of PTEN in
glioblastoma multiforme. Cancer Res.
57,4183
-4186.
Waridel, F., Estreicher, A., Bron, L., Flaman, J.M., Fontolliet, C., Monnier, P., Frebourg, T., and Iggo, R. (1997) Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 14,163 -169.[CrossRef][ISI][Medline]
Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6, 217-223.[ISI][Medline]
Watanabe, K., Sato, K., Biernat, W., Tachibana, O., Vonammon, K., Ogata, N., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3, 523-530.[Abstract]
Werner, H., Karnieli, E., Rauscher, F.J., and LeRoith, D.
(1996) Wild-type and mutant p53 differentially regulate
transcription of the insulin-like growth factor I receptor gene.
Proc. Natl. Acad. Sci. USA
93,8318
-8323.
Willert, J.R., Daneshvar, L., Sheffield, V.C., and Cogen, P.H. (1995) Deletion of chromosome arm 17p DNA sequences in pediatric high-grade and juvenile pilocytic astrocytomas. Genes Chromosomes Cancer 12,165 -172.[ISI][Medline]
Wu, J.K., Ye, Z., and Darras, B.T. (1993) Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery 33,824 -830.[ISI][Medline]
Xiao, Z.X., Chen, J., Levine, A.J., Modjtahedi, N., Xing, J., Sellers, W.R., and Livingston, D.M. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375,694 -698.[CrossRef][Medline]
Yahanda, A.M., Bruner, J.M., Donehower, L.A., and Morrison, R.S. (1995) Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol. Cell. Biol. 15,4249 -4259.[Abstract]
Yount, G.L., Haas-Kogan, D.A., Vidair, C.A., Haas, M., Dewey, W.C.,
and Israel, M.A. (1996) Cell cycle synchrony unmasks the
influence of p53 function on radiosensitivity of human glioblastoma cells.
Cancer. Res. 56,500
-506.
Zastawny, R.L., Salvino, R., Chen, J., Benchimol, S., and Ling, V. (1993) The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8,1529 -1535.[ISI][Medline]
Zhang, L., Kashanchi, F., Zhan, Q., Zhan, S., Brady, J.N., Fornace,
A.J., Seth, P., and Helman, L.J. (1996) Regulation of
insulin-like growth factor II P3 promotor by p53: A potential mechanism for
tumorigenesis. Cancer Res.
56,1367
-1373.
Zhang, S., Feng, X., Koga, H., Ichikawa, T., Abe, S., and Kumanishi, T. (1993) p53 gene mutations in pontine gliomas of juvenile onset. Biochem. Biophys. Res. Commun. 196,851 -857.[CrossRef][ISI][Medline]
This article has been cited by other articles:
|
|
 |
|
  F. Aloisio, J. M. Levine, and J. F. Edwards Immunohistochemical features of a feline spinal cord gemistocytic astrocytoma J Vet Diagn Invest, November 1, 2008; 20(6): 836 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Freedman, L. J. Wirth, L. R. Chirieac, and E. C. Huang Glioblastoma in a Patient With Early-Stage Tonsil Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2848 - 2850. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Afshar, N. Jelluma, X. Yang, D. Basila, N. D. Arvold, A. Karlsson, G. L. Yount, T. B. Dansen, E. Koller, and D. A. Haas-Kogan Radiation-Induced Caspase-8 Mediates p53-Independent Apoptosis in Glioma Cells. Cancer Res., April 15, 2006; 66(8): 4223 - 4232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Rich, C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B.K. A. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins, et al. Gene Expression Profiling and Genetic Markers in Glioblastoma Survival Cancer Res., May 15, 2005; 65(10): 4051 - 4058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Bobola, M. J. Emond, A. Blank, E. H. Meade, D. D. Kolstoe, M. S. Berger, R. C. Rostomily, D. L. Silbergeld, A. M. Spence, and J. R. Silber Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy Clin. Cancer Res., December 1, 2004; 10(23): 7875 - 7883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Landen, V. Hau, M. Wa |
